Cleveland BioLabs, Inc. (NASDAQ:CBLI) was downgraded by equities research analysts at ValuEngine from a “hold” rating to a “sell” rating in a report released on Thursday.

Shares of Cleveland BioLabs (CBLI) traded down 8.81% during mid-day trading on Thursday, reaching $3.00. 135,456 shares of the company traded hands. The stock’s 50-day moving average is $3.52 and its 200-day moving average is $2.37. Cleveland BioLabs has a 52 week low of $1.22 and a 52 week high of $5.55. The company’s market capitalization is $33.84 million.

Cleveland BioLabs (NASDAQ:CBLI) last announced its earnings results on Monday, May 15th. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter. The business had revenue of $0.58 million for the quarter. Cleveland BioLabs had a negative return on equity of 28.45% and a negative net margin of 111.40%. On average, equities analysts predict that Cleveland BioLabs will post ($0.16) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “ValuEngine Downgrades Cleveland BioLabs, Inc. (CBLI) to Sell” was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark laws. The original version of this news story can be accessed at

About Cleveland BioLabs

Cleveland BioLabs, Inc (CBLI) is a biopharmaceutical company. The Company is engaged in developing approaches to activate the immune system and address serious medical needs. Its platform of Toll-like immune receptor activators has applications in mitigation of radiation injury and immuno-oncology. Its advanced product candidate is Entolimod, an immuno-stimulatory agent, which it is developing as a radiation countermeasure and an immunotherapy for oncology and other indications.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Cleveland BioLabs Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cleveland BioLabs Inc. and related companies with's FREE daily email newsletter.